change
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ARDM - TA Elliott Wave 26.11.2010
Time frame-Cycle: Primary
EASI: positive
Trend: UP
Wave: 2
Target 1: $0.3166
Target 2: $0.5975
So, Let's Go ;)
Short interest decreased -55,70% from 959.400 to 425.000 shares!
http://www.shortsqueeze.com/?symbol=ardm&submit=Short+Quote%99
Aradigm is in discussions with potential partners for inhaled liposomal ciprofloxacin for further development and commercialization of this once daily inhaled antibiotic treatment. Aradigm also seeking government contracts for the use of this medication as prophylaxis and treatment against inhaled bioterrorism infections.
Aradigm believes that the AERx technology platform is a valuable asset. Aradigm continues to make efforts on the business development front to license or sell assets related to the AERx technology either as individual products (for example inhalation delivery of insulin which was developed in a collaboration between Aradigm and Novo Nordisk), or as a technology platform.
Aradigm preferred option to fund Phase 3 studies with inhaled liposomal ciprofloxacin is through partnerships with pharmaceutical companies.
Aradigm owed Novo Nordisk a little over $9 million for a loan that he got from them in 2006. The conversion of the common stock for the whole debt was the result of a negotiated agreement between Novo Nordisk and Aradigm (hence ~ 26 million shares at $0.35/share). Further details of this conversion are provided in his publicly available filings. The recently sold 1,369,550 shares of Aradigm by Novo Nordisk were shares that the US subsidiaries of Novo Nordisk held for many years; they were not shares from the debt to equity conversion completed this year!
Aradigm has no idea (not related to the recent development in Aradigm) why they sold at ~$0.165/share, but the shares of Aradigm they held were a part of a series of transactions between the two companies while they were jointly developing inhaled insulin; the Novo Nordisk subsidiary in Hayward was shut down in ~2007 when Novo Nordisk pulled out of development of inhaled insulin.
Aradigm is busy with their discussions with potential partners and with regulatory authorities.
It is possible any of these discussions will result in material disclosures before Christmas; before/with/after results Phase IIb ILC ORBIT-1 studies.
The results Phase 2b ORBIT-1 ILC trials should be announced by the end of the year.
Short interest is 959.400 shares still.
http://www.shortsqueeze.com/?symbol=ardm&submit=Short+Quote%99
I expect a significant short squeeze soon :)
Conference Call - November 22, 2010
PAION will hold a conference call today, Monday, 22 November 2010 at
10 a.m. CET (9 a.m. GMT, 4 a.m. ET) for media representatives and
shareholders in German. PAION will also be available for analysts and
investors in a further conference call in English at 4 p.m. CET.
PAION will host the conference calls to present details on the headline data of
the Phase IIb study with Remimazolam.
To access the call, please dial:
Germany +49 (0) 69 710445598
UK +44 (0) 20 3003 2666
US + 1 866 966 5335
(other countries: please choose from D/UK/US numbers).
The participant pass code is “PAION”.
To allow for smooth processing we suggest that you dial in ten minutes before
the beginning of the call.
The conference call will be supplemented by a webcast presentation which
can be accessed during the call under the following link:
www.meetingzone.com/presenter/
For the call at 10 a.m. CET, please use the PIN 1961272.
For the call at 4 p.m. CET, please use the PIN 4349347.
The dial-in details for the conference call and the webcast link are also
available on PAION’s website http://www.paion.com
The conference call will be recorded. Details on how to access the replay will
be posted on the same web page after the call.
PAION reports positive results of its short acting anaesthetic/sedative Remimazolam (CNS 7056) in a Phase IIb study
http://www.paion.de/images/stories/investoren/finanznachrichten/2010/en/paiona101119en.pdf
I have not other favourite bio stocks from Germany at present.
Look at my some favourite stocks in my profile.
I can order in USA, Germany ...
Hi Erbse,
Thank you for your info.
I am from Middle Europe. I have accumulated a PAIONs shares already. I hold and wait untill announcement of Remimazolam Phase IIb trial results. I believe they will be positive again ;)
The board with your nick "gurke24448" is also here
http://www.ariva.de/paion-aktie
Or not?
P.S. I am looking for undervalued stocks (especially biostocks with very good pipeline) with high potential within 1-3 years.
Good luck!
You are welcome, Erbse.
Sie sind herzlich wilkommen, Erbse.
Ich warte für Remimazolam ergebnisse bis ende November 2010.
New Form 4 (42.857 shares acquired + 150.000 shares per $0,175 stock option (Right to buy).
http://investor.aradigm.com/releasedetail.cfm?ReleaseID=520649
Big short interest 959.400 shares still today.
http://www.shortsqueeze.com/?symbol=ardm&submit=Short+Quote%99
Get ready for results Phase IIb ILC ORBIT-1 trials by the end of the year 2010.
The recent results Phase IIb ILC ORBIT-2 trials are very positive.
http://investor.aradigm.com/releasedetail.cfm?ReleaseID=520649
Get ready for Short squeeze - rapid increase in the price of a stock, especially due expected positive results ORBIT-1 trials!
Big short interest 959.400 shares!
http://www.shortsqueeze.com/?symbol=ardm&submit=Short+Quote%99
Get ready for Short squeeze - rapid increase in the price of a stock!
PA8 is today's Trade Alert with +500% potential!
Very good opportunity for an accumulation now. Thank you all sellers ;)
Get ready for results Phase IIb - Remimazolam (CNS 7056).
Headline data expected by end of November 2010.
It looks like an accumulation at this level before big run up. Target $0,065-$0,085?
Expected next earnings release:
1) 11/11/2010, BM - by Ameritrade (unaudited)
2) 11/18/2010, BM - by WSH (unaudited)
Maybe they will try to buy cheaper and more shares of ARDM when ILC trials are still positive and ...
The most important is that Novo Nordisk converted a $9.1 million debt into 26 million Aradigm shares for $0.3505 per share. They are not crazy.
By the way, Novo Nordisk sold 401,469 shares per $0,1711 (Nov 5, 2010).
http://files.shareholder.com/downloads/ARDM/1012156554x0xS950103-10-3300/1013238/950103-10-3300.pdf
But, who has bought 1.369.650 shares from Novo Nordisk till today? The clever investor or persons close to ARDM?!
Get ready for earnings Nov 11, 2010 and next events.
You are not true about funding. Even FEVIBMF did not sell shares at present!
It looks like you want buy ARDM cheaper. Me too. But you should write true!
Please hold the facts and events.
e.g. an actual S-1/A filing (Nov 8, 2010)
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0000950123%2D10%2D102372%2Etxt&FilePath=%5C2010%5C11%5C08%5C&CoName=ARADIGM+CORP&FormType=S%2D1%2FA&RcvdDate=11%2F8%2F2010&pdf==
Amount of shares to be registered 68,229,726. Consists of shares to be offered by selling shareholders. Consists of (a) 34,702,512 outstanding shares of common stock issued in a private placement that closed on June 21, 2010 (the “June 2010 private placement”), (b) 7,527,214 outstanding shares of common stock that were issued upon exercise of warrants issued in the June 2010 private placement and (c) 26,000,000 outstanding shares of common stock that were issued under a stock purchase agreement, dated as of July 30, 2010, by and among the Registrant and Novo Nordisk A/S. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), there is also being registered hereby such indeterminate number of additional shares of common stock as may be issued or issuable because of stock splits, stock dividends, stock distributions, and similar transactions.
In the Novo Nordisk A/S knows that ARDM value is a lot above $50 Mio with ILC.
~$50 Mio is only AERx asset and that is why Novo Nordisk converted a $9.1 million debt into 26 million Aradigm shares for $0.3505 per share.
Aradigm seeks a new partner or acquirer of the AERx iDMS asset...
For more information see my post #1001 http://investorshub.advfn.com/boards/read_msg.aspx?message_id=55972197
I am afraid, you are not right about funding.
1) Aradigm Announces Exercise of Warrants for Proceeds of Approximately $891,000 (Sep 23, 2010)
2) Aradigm Awarded Three Therapeutic Discovery Tax Credit Grants Totaling Over $733,000 for Inhaled Liposomal Ciprofloxacin Program (Nov 2, 2010)
3) The royalties for ARDM $0,598 Mio (Nine Months Ended September 30, 2010 by Zogenix)
http://www.sec.gov/Archives/edgar/data/1375151/000119312510247019/ds1a.htm
It is in line with expectations.
Sales of SUMAVEL DosePro increase each month (see below).
However, this is NON-strategic for ARDM. :)
The royalties for ARDM $0,598 Mio (Nine Months Ended September 30, 2010 by Zogenix)
http://www.sec.gov/Archives/edgar/data/1375151/000119312510247019/ds1a.htm
The royalties for ARDM $0,382 Mio (Six Months Ended June 30, 2010 by Zogenix)
http://www.sec.gov/Archives/edgar/data/1375151/000119312510204697/ds1.htm
Full stochastic and CCI signalize UP trend, MACD should signalize UP trend within 1-3 days.
I have accumulated a huge amount of shares already. This is one from my favorites. ARDM is undervalued. Only AERx assets is around $50 Mio. And with pipeline ...
Get ready for earnings Nov 11, 2010.
Aradigm Appoints Tamar Howson to Board of Directors
Well-Known Industry Expert Strengthens Business Development Focus
http://investor.aradigm.com/releaseDetail.cfm?ReleaseID=526967
Novo Nordisk (> 10% owner) owns 27,337,266 shares following this transaction. This is important, NOT sale of 236,406 shares (< 0,86%) Nov 1, 2010.
Maybe Novo Nordisk Delivery Technologies Inc. will try to buy more shares cheaper. I do not know. It is exchange. But, nobody can guarantee they will be succesful.
Novo Nordisk Delivery Technologies Inc. is a wholly-owned subsidiary of Novo Nordisk A/S. Novo Nordisk A/S directly holds 26,204,122 shares of common stock of Aradigm Corporation. In addition, Novo Nordisk Inc. holds 1,133,144 shares of common stock of Aradigm Corporation.
#
The sales of SUMAVEL DosePro increase = more and more royalties for ARDM untill January, 2020.
The results of trials Phase 2b ORBIT-2 (ARD-3100 and ARD-3150) are very positive.
Aradigm Awarded Three Therapeutic Discovery Tax Credit Grants Totaling Over $733,000 for Inhaled Liposomal Ciprofloxacin Program (announced Nov 2, 2010).
"The cash we receive from these awards is a reflection of our focus on generating non-dilutive funds. We are pleased that the HHS review recognized that our inhaled liposomal ciprofloxacin programs show promise to treat areas of unmet medical needs," said Igor Gonda, the Company's President and Chief Executive Officer.
In October 2010, the Company reported positive top line data from its ORBIT-2 Phase 2b 6-month clinical trial of ARD-3150 in 42 BE patients. The Company previously reported positive results in Phase 2a studies of 22 CF patients and 36 BE patients who received ARD-3100 once-a-day for 2 (CF) or 4 (BE) weeks, respectively.
A double-blind, placebo-controlled study in 96 bronchiectasis patients treated with ARD-3100 for 28 days (ORBIT-1) is currently underway. "We expect to be able to announce data from this trial by the end of the year." said Igor Gonda, the Company's President and Chief Executive Officer.
I hope you can see again, I have posted a correct and serious informations about ARDM in past.
Believe me, ARDM is pretty undervalued now.
And, I do not expect any dilution of shares in near future. There is no reason.
Aradigm Awarded Three Therapeutic Discovery Tax Credit Grants Totaling Over $733,000 for Inhaled Liposomal Ciprofloxacin Program
http://investor.aradigm.com/releaseDetail.cfm?ReleaseID=525930
ARDM expects very positive trend of royalties based on sales of SUMAVEL DosePro by Zogenix, Inc. and Astellas Pharma US, Inc. (by a source close to ARDM).
ALERT - ARDM is oversold! ARDM should go up to level $0,29 quickly.
Target is above $1 within few month and above $3 in 2011/2012.
Do not sell shares so low.
You should follow institutional investors, insiders and Novo Nordisk (NVO). All they acquired huge amount shares, e.g. Novo Nordisk A/S 26 Mio shares per $0,3505.
Why? ARDM is very perspective investment and they know it very well also. Me too.
Please, read my earlier posts. ARDM is undervalued. I recomend STRONG BUY.
There is not new information. Don't panic!
See prior Registration Statement S-1 (Aug 11, 2010).
http://investor.aradigm.com/secfiling.cfm?filingID=950123-10-95719
ARDM is ten-bagger stock by the end of the year 2011-2012.
I can not believe some people sell shares so low, especially after succesfull results Phase 2b (ORBIT-2) trials. Buyers are very satisfied. I do not sell and I accumulate. I have expected price of shares around $0.32-0.45 level by the end of the year 2010.
By the way, only AERx iMDS asset is around $50 Mio and if the Mannkind product AFREZZA(R) will be approved 29/12/2010 it should be more. Of course, Aradigm seeks a new partner or acquirer of the AERx iDMS asset and CEO Mr. Igor Gonda very well know about benefits for ARDM if AFREZZA(R) will be approved. AERx iMDS asset will be very attractive for new partner or acquirer.
I think this is real reason why Novo Nordisk acquired 26 Mio shares of ARDM for $0,3505.
Forget for $0,11 level now. It is past.
Get ready for Earnings (I think 13/11/2010)
Get ready for results Phase 2b (ORBIT-1) by the end of the year 2010.
Get ready for announcement Phase 3 trials.
Get ready for more news.
Get ready for "Gap Up".
ARDM has big potential:
* More and more royalties from sales SUMAVEL DosePro from Zogenix until January 2020.
* Pipeline - succesful Phase 2b trials with Inhaled Liposomal Ciprofloxacin.
* AERx iMDS asset.
Believe The Facts.
Mannkind product - AFREZZA(TM)
http://www.reuters.com/article/idUSSGE66J0HK20100720
SEC Filing Form-4
http://www.investors.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-SECText&TEXT=aHR0cDovL2lyLmludC53ZXN0bGF3YnVzaW5lc3MuY29tL2RvY3VtZW50L3YxLzAwMDEyMDkxOTEtMTAtMDUxMjYxL3htbC9zdWJkb2N1bWVudC8xL3BhZ2UvMQ%3d%3d
Aradigm seeks a new partner or acquirer of the AERx iDMS asset.
Novo Nordisk may very well change their minds about inhaled insulin if the Mannkind product gets approved but at present the fact that Novo Nordisk is a shareholder of Aradigm gives them no special rights for this asset.
(wrote CEO Mr. Igor Gonda today)
http://www.aradigm.com/products_iDMS.html
http://www.reuters.com/article/idUSN1443991020080114
I expect ARDM will receive from Zogenix around $1 Mio. of royalties by the end of the year 2010 and in orders of $Mio. in each year up to January, 2020.
This and especially positive results from trials ORBIT-2 and expected positive results from trials ORBIT-1 should lead to SIGNIFICANT increase price of shares soon.
I expect Gap Up soon.
You are absolutely right!
I can not believe the price is too low after succesfull trials ORBIT-2!
However, this is very good opportunities to accumulate shares, before results ORBIT-1 and more news by the end of the year. I accumulate.
I follow institutional investors and insiders. I wait for great news like they soon.
ARDM is my big favorite and next ten-bagger stock ;)
Aradigm Reports Successful Phase 2b Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin
http://investor.aradigm.com/releaseDetail.cfm?ReleaseID=520649
ARDM Chart pattern - Cup with Handle - BREAKOUT
The Cup with Handle is a bullish continuation pattern that marks a consolidation period followed by a breakout.
http://stockcharts.com/help/doku.php?id=chart_school:chart_analysis:chart_patterns:cup_with_handle_cont
RESULTS BY THE END OF THE NOVEMBER 2010.
The Paion AG will announce results of the Phase IIb clinical trial assessing the new short-acting intravenous anesthetic/sedative Remimazolam (CNS 7056) in patients undergoing colonoscopy.
No drug-related Serious Adverse Event has been reported.
Aradigm Will Announce Third Quarter 2010 Financial Results In November 11, 2010